Abstract
INTRODUCTION
Gilbert's syndrome (GS) is generally considered to be an autosomal recessive disorder (OMIM #143500) ch a r a c t e r i z e d by m i l d , ch r o n i c, n o n -h e m o l y t i c unconjugated hyperbilirubinemia in the absence of liver disease. Although it has long been perceived to be an innocuous clinical entity with a benign course, recent data suggest that affected individuals may be predisposed to development of liver injury following treatment with various drugs and xenobiotics and that the genetic defect in GS may influence the outcome of liver transplantation and other clinical conditions. The disorder due to a defi ciency in bilirubin glucuronidation, is commonly caused by dinucleotide (TA) insertions and [TA (TA)7TAA] alleles in the promoter region of the bilirubin UDP-glucuronosyltransferase 1 (UGT1A1) gene. This dinucleotide insertion reduces the efficiency of transcription of the gene and decreases hepatic UDPglucuronosyltransferase activity to about 30% of normal levels in homozygous subjects [6] [7] [8] [9] . The prevalence of GS, the frequency of the (TA)7TAA allele in the UGT1A1 promoter and the proportion of GS patients who are homozygous for the (TA)7TAA allele vary widely across populations [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Recent data have also shown that variants in UGT1A1 gene other than the classical dinucleotide insertion in its promoter, can contribute to hyperbilirubinemia, including the milder form as in GS, although their effects appear to be variable across populations [5, [20] [21] [22] [23] [24] . Thus, as recently emphasized [20] , detailed investigations into genetic polymorphisms of UGT1A1 gene in Asian populations may provide a better understanding of unconjugated hyperbilirubinemia.
The objectives of our case-control study were to estimate the association between homozygosity for the (TA)7TAA allele and GS in India, to identify and study the impact of this and other polymorphisms in the promoter and exons of the UGT1A1 gene on serum bilirubin levels, and to estimate the frequency of the (TA)7TAA homozygous genotype in the general population in India.
MATERIALS AND METHODS

Participant recruitment and clinical biochemistry analysis
This study was conducted in 95 consecutive patients presenting to the Liver Clinic at the Department of Gastroenterology of the Institute of Postgraduate Medical Education & Research, Kolkata, India, for evaluation of persistent unconjugated hyperbilirubinemia (serum bilirubin greater than 1.2 mg/dL) documented at least twice over a period of one month. Serum total bilirubin and its unconjugated fraction were estimated in fasting condition. Each of these individuals had a normal fi nding on physical examination, normal hepatobiliary ultrasound, normal liver function test excluding hyperbilirubinemia and a normal reticulocyte count. A total of 95 adult healthy volunteers from the same ethnic population as the GS patients were included as controls. Each control also underwent the same set of investigations as the patients. Their fasting serum bilirubin level estimated twice at intervals of fi fteen days was consistently less than 1.0 mg/dL. Patients were excluded if they were under any medication during the past one month or consumed alcohol regularly or had present or past history of hepatic/hematological disease. Additionally, quantitative estimation of hemoglobin fractions (A0, A2 and F) was carried out on each patient and control by cation-exchange HPLC using the Variant TM Hemoglobin Testing System Beta Thalassemia Short Program (Bio-Rad Diagnostics, Hercules, USA). A 5 mL blood sample was collected from each patient by venipuncture and DNA was isolated using a standard protocol [25] . Data and samples were collected with written informed consent of the patients and controls, after the approval was obtained from the Human Research Ethics Committee of the Institute of Postgraduate Medical Education & Research, Kolkata.
DNA re-sequencing and identifi cation of variant alleles DNA re-sequencing of the promoter and exon 1*1 encoding the substrate-specifi c region of bilirubin-UGT1 gene as well as the 4 common exons (exons 2-5) was carried out using an automated DNA sequencer (ABI-3100; Applied Bio-systems, Foster City, USA.). DNA samples were first amplified by the polymerase chain reaction technique using an ABI-9700 thermal cycler. PCR products were then cleaned using exonuclease-I (USB. Corporation, Cleveland, USA) and shrimp alkaline phosphatase (Amersham, Freiburg, Germany), and sequencing reactions were carried out. DNA resequencing was carried out in both forward and reverse directions. Raw DNA sequences were analyzed as previously described [26] , and variant genotypes were identifi ed.
Functional analysis of a novel trinucleotide insertion by luciferase reporter assay UGT1A1 promoter fragments, 331-336 bp in length depending on the number of TA repeats and CAT insertion, were amplifi ed using primers (F: 5'-tgtagatcttcct ctctggtaacact-3') and (R: 5'-atgaagctttgctcctgccagaggttc-3') from genomic DNA of individuals homozygous for six and seven TA repeats, and CAT insertion on (TA)7TAA background. DNA amplification was carried out with polymerase chain reaction (PCR) using FastStart Taq DNA polymerase (Roche, Mannheim, Germany) with an initial denaturation at 95 ℃ for 10 min, followed by 35 cycles at 94 ℃ for 1 min, at 56 ℃ for 45 s and at 72 ℃ for 30 s on an ABI-9 700 (Applied Bio-systems, Foster City, USA.) thermal cycler. To facilitate subcloning of the PCR products in the reporter gene construct, oligonucleotides F and R were designed with a Bgl II and a Hind III restriction enzyme site at the 5' end, respectively. PCR products were doubly digested with Bgl II and Hind III, purifi ed by Qiagen gel purifi cation kit (Qiagen, Hilden, Germany) and subcloned into pGL3-basic vector (Promega, Madison, USA). The integrity of the resulting plasmids was confi rmed by restriction mapping and sequencing analyses. Promoter activity of each construct was measured in HepG2 cell line. Cells were grown in MEM medium supplemented with 2 mmol/L L-glutamine, 0.1 mmol/L non-essential amino acids, 1 mmol/L sodium pyruvate and 10% fetal calf serum (GIBCO -BRL, Grand Island, USA) at 37 ℃ with 50 mL/L CO2. Exponentially growing cells were trypsinized, seeded at 2.5×10 5 cells, and incubated overnight prior to transfection. Transfection was carried out by lipofectamin (Invitrogen, Carlsbad, USA) using 2 μg of each of the constructs (namely (TA)6 TAA, (TA)7 TAA and CAT insertion on (TA)7 TAA background), as well as the pGL3-basic and pGL3-control as positive controls (TA)7TAA, the luciferease gene was under the control of SV40 promoter and enhancer. After 48 h of transfection, the cells were lysed and centrifuged in cell culture lysis buffer (Promega, Madison, USA). Luciferase activity was assayed in the cell lysate by measuring the photoluminescence in a Monolight 2010 single channel luminometer and the total cellular protein content was measured by the standard Bradford's method. Luciferease activity was normalized to total cell protein concentration. Normalized luciferase activity of each construct was expressed as a ratio to that of the pGL3-basic vector. Three independent experiments were performed for each construct and all measurements were determined in duplicate.
Statistical analysis
Equality of proportions was statistically tested by the standard normal test procedure [27] . Equalities of mean values of various hematological parameters for individuals belonging to different genotypes at various polymorphic loci were statistically tested using the Student t-test or the analysis of variance (ANOVA) procedure, as appropriate. Regression analysis was performed to test the signifi cance of dependence of un-conjugated serum bilirubin level on some relevant variables. Allele frequencies were estimated using the gene-counting method.
RESULTS
Characteristics of patients and controls
No statistically significant (P > 0.05) differences in the proportions of males and females were observed between the patients (87 males, 8 females) and controls (77 males, 18 females). The mean ages of male and female patients (30.1 ± 1.1 years of males, 26.8 ± 5.1 years of females) and controls (30.2 ± 1.1 years of males, 31.1 ± 2.9 years of females) were not significantly different (P > 0.05).
Since elevated HbA2 levels could potentially increase the unconjugated bilirubin level, we tested the signifi cance of the regression coeffi cient of HbA2 level on unconjugated bilirubin, separately for patients and controls. In both sets, there was no statistically significant impact of HbA2 (P-values for patients and controls were 0.638 and 0.106, respectively). The difference in the mean values of HbA2 between patients and controls was not signifi cantly different (t = 1.76, d.f. = 128, P > 0.05). The 8 GS patients, but none of the normal controls, who were habitual smokers were asked to refrain from smoking for 24 h prior to blood collection. We tested whether the inclusion of these 8 GS patients had a significant impact on our fi ndings. We therefore, examined whether the mean value of un-conjugated bilir ubin among patients who were smokers (n = 8) was significantly higher than that among patients who were not smokers (n = 87). No significant difference was found (mean for smoker patients=2.67 ± 0.33, mean for non-smoker patients = 3.38 ± 0.30, t = 0.696, d.f. = 93, P = 0.488). We have performed all analyses that were reported below with and without the inclusion of the 8 GS patients who were habitual smokers. No differences in inferences were found (results not shown). Therefore, we presented all results including these 8 GS subjects.
UGT1A1 sequence variants and their relation with bilirubin level
Eleven sequence variants in UGT1A1 gene was observed, of which 3 each were in the promoter, 3 in exon 1, 2 in exon 2, 1 in exon 3 and 2 in exon 4. No variant was found in exon 5. The genotype and variant allele frequencies at these positions in patients and controls are given in Table  1 . Of these 11 variant sites, 2 were non-polymorphic (frequency of the rarer allele < 1%), while the remaining 9 sites were polymorphic either among patients or among controls or in both. One of the polymorphic sites was the TA insertion [(TA)7TAA allele] in the TATA box of the UGT1A1 promoter [2, 3] . The frequencies of the (TA)7TAA allele (0.879) and the 7/7 genotype (80%) among the patients were significantly higher (P < 0.005) than those among the controls (0.384 and 10%, respectively). The un-conjugated serum bilirubin values for GS patients belonging to the 6/6, 7/6 and 7/7 genotypes are presented in Figure 1 . The mean values of un-conjugated bilirubin for GS patients and normal controls were 2.5 ± 0.25 mg/dL and 0.61 ± 0.09 mg/dL respectively. The mean+SE value of un-conjugated bilirubin among patients with the 7/6 genotype was 3.46 ± 0.54 mg/dL, which was not signifi cantly different (P = 0.05) from patients with the 7/7 genotype (3.31 ± 0.33 mg/dL). The mean un-conjugated serum bilirubin values for these genotypes among controls were only 0.59 ± 0.10 mg/dL and 0.64 ± 0.15 mg/dL, respectively.
No significant differences (P = 0.05) were found in the mean bilirubin levels among individuals belonging to the various genotypes at the remaining single nucleotide polymorphic loci. With respect to the C6844G polymorphism resulting in a non-synonymous amino acid change (A321G), all patients were CC homozygotes, while about 30% of the controls were CG heterozygotes ( Table 1) . We did not find any significant effect of the G71R polymorphism on un-conjugated bilirubin level. This polymorphism also showed no signifi cant interaction with the TATA box insertion polymorphism (results not shown). These fi ndings are discordant with those reported among the Japanese [19] .
A novel human-specifi c trinucleotide insertion in Gilbert's syndrome patients and its impact on bilirubin level
Among the polymorphic variants described in Table 1 , aside from the familiar TA insertion, the most striking was the CAT insertion (nucleotide positions -85 to -83) in the CAAT box of UGT1*1 promoter. Normally, there is one copy of the CAT trinucleotide present in human Genbank (http://www.ncbi.nlm.nih.gov/Genbank/). We found two copies of this trinucleotide in some GS patients. To confi rm that this was an insertion we searched the chimpanzee (gi|6456543|gb|AF135463.1|AF135463) and gorilla (gi|6456545|gb|AF135464.1|AF135464) databases. In both species there is only copy, confi rming that the single copy is the ancestral state. This CAT insertion was found only among nine (10%) GS patients, who were all homozygous for the TA insertion. We found that GS patients with the CAT-insertion had a signifi cantly (P < 0.001) elevated mean level (6.13 ± 1.61 mg/dL) compared to those without the insertion (2.93 ± 0.28 mg/dL). Individuals who possessed the CAT insertion did not consistently possess a variant allele at any of the other sites. One individual who was heterozygous for the CAT insertion was also heterozygous for the I322V variant, and other three CAT-insertion heterozygotes were also heterozygotes for the H376R variant.
Functional analysis of CAT insertion
Since about 10% of the (TA)7TAA homozygotes carried the CAT insertion and the insertion signifi cantly elevated the bilirubin level, we postulated that the insertion had a functional impact. To examine this, we studied the change in DNA-folding of the promoter region caused by this insertion. The most stable structures, namely those with lowest free energy (dG) values, are given in Figure 2 for the UGT1A1 promoter region without (dG = -14.4) and www.wjgnet.com
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with (dG = -14.8) the additional CAT insertion. A striking structural change was found around the region of the insertion, the loops were converted to stems. It is well known that formation of stems in the promoter could reduce transcription of the gene. A detailed functional analysis of the UGT1A1 promoter by luciferase reporter assay confirmed that there was a two-fold decrease in transcription efficiency for the variant (TA)7TAA promoter allele, and a 20-fold decrease when there was a CAT insertion in the promoter on the background of the (TA)7TAA allele compared to the normal (TA)6TAA promoter allele (Figure 3) .
DISCUSSION
Genetically determined un-conjugated hyperbilirubinemia constitutes a spectrum of clinical entities characterized by incremental serum bilirubin values related to graded reduction of UGT1A1 enzyme activity. The most novel finding of our study is that a trinucleotide (CAT) insertion in the nucleotide positions -85 to -83 of the UGT1A1 promoter was present in GS patients who were homozygous for the causal TA insertion, but not in other GS patients or in controls. This insertion significantly (P < 0.001) elevated the un-conjugated bilirubin level (mean = 6.13 mg/dL) in the patients to the range usually seen in Crigler-Najjar (CN) II syndrome. We have demonstrated that this insertion in the background of the (TA)7 allele classically described in GS, diminishes UGT1A1 transcriptional activity to about 5% (2.4 light units/10 3 μg protein) of the normal (44.9 light units/10 3 μg protein), much lower than the 50% reduction (22.9 light units/10 3 μg protein) observed for (TA)7 alone. Thus the combined biological effect of the CAT and TA insertions is a further elevation in the un-conjugated bilirubin level compared to that of the TA insertion alone, which is exactly what we have observed in the GS patients carrying the CAT insertion. This initial description of the interactive infl uence of a novel trinucleotide insertion and the GS-type abnormality in the promoter region alone, in the absence of a consistent exonic mutation, to quantitatively elevate un-conjugated bilirubin to levels observed in Crigler-Najjar II (CN II) provides further evidence of genetic heterogeneity and overlap of the clinical syndromes of un-conjugated hyperbilirubinemia. Thus, Gilbert's, Crigler-Najjar I (CN I) and CN II syndromes may not be mutually exclusive clinical-genetic entitities but are different windows of the quantititative spectrum of elevated serum unconjugated bilirubin levels.
The association (80%) between homozyg osity for the (TA)7TAA allele and GS is much stronger in India than reported earlier from most other ethnic groups [14, 15, 16, 20] . Graded reduction of UGT1 activity has been demonstrated with increasing length of the TA repeats in a recent study [28] . It was demonstrated that 7/7 homozygotes and 7/6 heterozygotes have, respectively, a 52% and a 37% reduction of UDP glucuronyl transferase activity in liver tissue homogenates. In our study, serum un-conjugated bilirubin values among 7/6 heterozygote GS patients were high but not signifi cantly different from the 7/7 homozygotes. The finding of increased serum bilirubin values among the 7/6 heterozygote GS patients to the same extent as those homozygous for the classically described 7/7 genotype, even in the absence of any other consistent change in the UGT1A1 gene, is intriguing. We could not explain this finding, but speculate the role of other interacting non-UGT1A1 genetic variants.
Although the insertion of additional TA repeats in the (TA)6 TAA promoter, sequence of the UGT1A1 gene is the most common variation associated with Gilbert's syndrome, (TA)5 and (TA)8 sequences in the TATAA box have also been found [4, 14] . We did not find (TA)5 and (TA)8 alleles in our study participants. Moreover, several mutations in the exons have been found in other populations, particularly from Asia, in association with GS and hyperbilirubinemia, either as the only abnormality or in addition to the more common promoter defect [20] [21] [22] [29] [30] [31] . We have identified several promoter and coding region (all non-synonymous) variants of the gene ( Table 1) . The G71R variant has been reported earlier [19, [22] [23] [24] , and the P364L variant has recently been reported in one Japanese GS patient [19] . Contrary to the finding among the Japanese [32] , the G71R change had no impact on unconjugated bilirubin level in our samples, nor did it interact with the dinucleotide (TA) insertion in the TATA box of the UGT1A1 gene. Many variants discovered in this study have not been reported earlier and many variants reported earlier were not found in the present sample. Although all the observed variations in exons could result in amino acid substitutions, none of these signifi cantly altered the mean bilirubin level. Thus, the UGT1A1 gene appears to tolerate a large number of mutations without any significant deleterious effect. None of these was strongly associated with the (TA)7TAA allele in our study. However, the amino acid change from isoleucine to valine at the amino acid position 322 was only found among the controls and not among the GS patients. Further studies are necessary to test whether this change helps bilirubin glucuronidation by the UGT1A1 gene.
The UGT1A1 polymorphisms have recently acquired signifi cance because they predispose individuals to altered metabolism and enhanced toxicity of several drugs like paracetamol, propofol, irinotecan, indinavir, etc, which are 
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Farheen S et al. Gilbert's syndrome and variants in UGT1A1 gene substrates for glucoronidation by UGT1A1 [33] [34] [35] [36] . Exons 2-5 are shared by other UGT1A transcripts and isozymes that mediate metabolism of xenobiotics apart from A1 involved in bilirubin glucuronidation [37] . The new variants in these exons may be relevant to drug metabolism, but we have not tested this. Our fi ndings reveal that it is crucial to carry out detailed surveys on genetic variations in and around the UGT1A1 gene and functional studies on these variants for a deeper understanding of quantitative anomalies of bilirubin.
